Eli Lilly and Company $LLY is Elm3 Financial Group LLC’s 6th Largest Position

Elm3 Financial Group LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 7.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 5,914 shares of the company’s stock after selling 503 shares during the period. Eli Lilly and Company comprises about 3.8% of Elm3 Financial Group LLC’s portfolio, making the stock its 6th biggest holding. Elm3 Financial Group LLC’s holdings in Eli Lilly and Company were worth $4,611,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Drake & Associates LLC increased its position in Eli Lilly and Company by 6.4% in the second quarter. Drake & Associates LLC now owns 900 shares of the company’s stock worth $702,000 after buying an additional 54 shares during the last quarter. Mraz Amerine & Associates Inc. grew its stake in shares of Eli Lilly and Company by 19.1% during the 2nd quarter. Mraz Amerine & Associates Inc. now owns 312 shares of the company’s stock worth $243,000 after acquiring an additional 50 shares during the period. KPP Advisory Services LLC increased its holdings in Eli Lilly and Company by 11.6% in the 2nd quarter. KPP Advisory Services LLC now owns 3,535 shares of the company’s stock worth $2,756,000 after acquiring an additional 368 shares during the last quarter. D.B. Root & Company LLC raised its stake in Eli Lilly and Company by 75.4% in the 2nd quarter. D.B. Root & Company LLC now owns 691 shares of the company’s stock valued at $539,000 after acquiring an additional 297 shares during the period. Finally, Capital Advisors Inc. OK lifted its holdings in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $938.94.

Insider Activity

In other news, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Up 0.7%

NYSE LLY opened at $845.40 on Tuesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The stock has a market capitalization of $800.14 billion, a PE ratio of 55.25, a PEG ratio of 1.17 and a beta of 0.47. The business’s 50-day moving average is $735.35 and its 200 day moving average is $765.48.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 earnings per share. Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.